Publication: Oral anticoagulation in octogenarians with atrial fibrillation.
No Thumbnail Available
Identifiers
Date
2016-08-04
Authors
Hugo, González Saldivar
Figueiras-Graillet, Lourdes M
Anguita, Manuel
Marín, Francisco
Bertomeu, Vicente
Roldán, Inmaculada
Ruiz, Martín
Muñiz, Javier
Martínez-Sellés, Manuel
FANTASIIA registry investigators (see Appendix)
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Vitamin K antagonists (VKAs) are still largely employed, even in nonvalvular atrial fibrillation (AF). Our aim was to study the clinical profile of octogenarians treated with oral anticoagulation and to study the effect of age on the quality of VKAs anticoagulation. Data are from a prospective national registry in an adult Spanish population of nonvalvular AF. We included 1637 patients who had been receiving VKAs for at least 6months before enrolment. Mean age was 73.8±9.4years. Patients aged >80years (N=429) had a high risk profile with higher risk of stroke and bleeding than younger patients; CHA2DS2-VASc (Cardiac failure, Hypertension, Age>74, Diabetes, Stroke, Vascular disease, Age 65-74years, and Sex category) 4.5±1.3 vs. 3.5±1.6, p80years (N=429) had a high risk profile with higher risk of stroke and bleeding than younger patients; CHA2DS2-VASc (Cardiac failure, Hypertension, Age>74, Diabetes, Stroke, Vascular disease, Age 65-74years, and Sex category) 4.5±1.3 vs. 3.5±1.6, p74, Diabetes, Stroke, Vascular disease, Age 65-74years, and Sex category) 4.5±1.3 vs. 3.5±1.6, p64years), Drugs/alcohol concomitantly) 2.4±0.9 vs. 1.9±1.1, p In this large registry octogenarians with nonvalvular AF had high risk of stroke and bleeding and frequent renal disease. VKAs anticoagulation quality was similar in octogenarians and in younger patients.
Description
MeSH Terms
Administration, Oral
Age Factors
Aged
Aged, 80 and over
Anticoagulants
Atrial Fibrillation
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Incidence
Male
Prospective Studies
Registries
Risk Assessment
Risk Factors
Spain
Stroke
Survival Rate
Treatment Outcome
Age Factors
Aged
Aged, 80 and over
Anticoagulants
Atrial Fibrillation
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Incidence
Male
Prospective Studies
Registries
Risk Assessment
Risk Factors
Spain
Stroke
Survival Rate
Treatment Outcome
DeCS Terms
CIE Terms
Keywords
Age, Atrial fibrillation, Octogenarians, Time in therapeutic range, Vitamin K antagonists